anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Patients receive PI3K Inhibitor BKM120 PO QD on days 1-21, cisplatin IV over 2 hours on day 1 and etoposide IV over 1 hour on days 1-3. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
The present invention relates to the technical field of medicine, which is a common anemarrhena rhizome extract and a preparation method thereof and an application for preparing diabetes medicine by using the common anemarrhena rhizome. A common anemarrhena rhizome medicinal material is processed by heat extracting or cold soaking by using water containing ethanol. By macroporous resin adopted for separation, a common anemarrhena rhizome extract is refined. The main active components of the common anemarrhena rhizome extract contain mangiferin and new mangiferin, wherein the total content of the mangiferin and new mangiferin reaches 50%, and the content ratio of the mangiferin and the new mangiferin is 1:1 to 5:1. By animal experiment, diabetes can be effectively prevented and cured. The common anemarrhena rhizome extract can be used for preparing diabetes medicine.
BACKGROUND: Vasculogenic mimicry (VM) is an angiogenesis-independent process that potentially contributes to the poor clinical outcome of anti-angiogenesis therapy in multiple malignant cancers, including pancreatic adenocarcinoma (PAAD). Several studies have shown that ginsenoside Rg3, a bioactive component of ginseng, holds considerable potential for cancer treatment. Our previous work has proved that Rg3 can inhibit VM formation in PAAD. However, its underlying mechanism remains unclear.
PURPOSE: To explore the underlying mechanism by which Rg3 affects VM formation in PAAD.
METHODS: We first investigated the effects of Rg3 on the cellular phenotypes of two PAAD cell lines (SW-1990 and PCI-35), and the expression of EMT- and stemness-related proteins. SW-1990 cells were adopted to construct xenograft models, and the anti-tumor effects of Rg3 in vivo were validated. Subsequently, we isolated the exosomes from the two PAAD cell lines with Rg3 treatment or not, and explored whether Rg3 regulated VM via PAAD cell-derived exosomes. MiRNA sequencing, clinical analysis, and rescue experiments were performed to investigate whether and which miRNA was involved. Subsequently, the target gene of miRNA was predicted using the miRDB website (https://mirdb.org/), and rescue experiments were further conducted to validate those in vitro and in vivo.
RESULTS: Rg3 indeed exhibited excellent anti-tumor effects both in vitro and in vivo, with inhibitory effects on EMT and stemness of PAAD cells. More interestingly, Rg3-treated PAAD cell-derived exosomes suppressed the tube-forming ability of HUVEC and PAAD cells, with a decrease in stemness-related protein expression, indicating that Rg3 inhibited both angiogenesis and VM processes. Subsequently, we found that Rg3 induced the up-regulation of miR-204 in PAAD cell-derived exosomes, and miR-204 alone inhibited tube and sphere formation abilities of PAAD cells like exosomes. Specifically, miR-204 down-regulated DVL3 expression, which was involved in regulating cancer cell stemness, and ultimately affected VM. The in vivo experiments further indicated that Rg3-treated SW-1990 cell-derived exosome-inhibited tumor growth, VM formation, and stemness-related protein expression can be abrogated by DVL3 overexpression.
CONCLUSION: Ginsenoside Rg3 increased the PAAD cell-derived exosomal miR-204 levels, which subsequently inhibited its target genes DVL3 expression in the receptor PAAD cells, and the down-regulated DVL3 broke stemness maintenance, ultimately suppressing VM formation of PAAD. Our findings revealed a novel mechanism by which Rg3 exerted its anti-tumor activity in PAAD via inhibiting VM, and provided a promising strategy to make up for the deficiency of anti-angiogenesis therapy in cancer.
Cosmetic or therapeutic preparations in the form of powders containing microorganism metabolic products are prepared by stirring a conventional inorganic or organic cosmetic or therapeutic powder base with a fermentation broth, which contains the desired active ingredient(s) and which is free from solids, to form a pulp which is then spread to obtain as large a surface area as possible and is maintained at 20-25 DEG C. for 5-15 days in an atmosphere having a relative humidity of 80-100%, before being dried and ground.  The powder base may be an urea-formaldehyde resin, talcum, or levelite (which is silica having a particle size of 0.003m ).  The fermentation broth may be that described in Specification No. 984,897 or No. 1,008,281.  The powder obtained in the Example by treating silica with fermentation broth according to Specification No. 984,897, is stated to be highly active against inflammatory conditions in the mouth, skin eczema, mycosis, and unpleasant odours, especially odours of the body.
This 2 week arm is the placebo part of the crossover design. Subjects receive placebo in a manner similar to the MPH arm. It lasts 2 weeks.
PURPOSE:To extract a plant extract containing coikisol or its precursor in high yield. CONSTITUTION:Carbon dioxide is supplied from a gas cylinder 1 through a cooler 3, a high-pressure pump 5 and a coil 7, made into a fluid in a subcritical or supercritical state and sent to an extracting tank 9 charged with an extracting raw material. A plant extract containing coikisol in high concentration is extracted from the extracting raw material with the carbon dioxide. The carbon dioxide in which the extract is dissolved is sent through a pressure retention valve 15 into a separating tank 19 and evacuated into a vapor-phase liquid. The plant extract is separated from the carbon dioxide gas and retained in the separating tank 19. The plant extract is recovered from the valve 21.
PURPOSE:To obtain a Chinese drug extract having high solubility, by extracting a Chinese drug with an extraction solvent, adding a specific nonionic surfactant to the extracted liquid or its concentrate, drying the mixture and optionally mixing with a vehicle. CONSTITUTION:A Chinese drug is extracted with an extraction solvent. The extracted liquid or its concentrate is added with a nonionic surfactant having an HLB of >= 7 (e.g. polyoxyethylene sorbitan fatty acid ester, polyoxyethylene glycerol fatty acid ester, etc.), dried by vacuum drying, freeze drying, etc., and mixed with a proper vehicle (e.g. sugar, starch, cellulose, etc.) to obtain the objective Chinese drug extract agent. The amount of the nonionic surfactant is preferably 0.3-5%. A Chinese drug extract agent having high solubility can be produced by this process.
<P>PROBLEM TO BE SOLVED: To provide a low invasive method for arranging a delivery system substantially adjacently to a vascular tissue, and to provide the delivery system used in the method.  <P>SOLUTION: The delivery system is formed into a flexible biological structure equipped with a soft tether means. The delivery system is, for example, inserted percutaneously into a space near the vascular tissue, such as a peritoneal tissue. When the delivery system is inserted thereinto, a tether pulls the delivery system toward the vascular tissue, so that the delivery system is fastened to the vascular tissue. A front surface of the delivery system is kept on being contacted with the vascular tissue in a state of being substantially pulled by the tether. The delivery system realizes continuous delivery of an active substance.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Lymphoglandular complexes are components of the gut-associated lymphoid tissue that are characterized by submucosal lymphoid aggregates invested by projections of mucosal epithelium. Reports of pathology involving these structures are rare in both human and veterinary literature. Here, the authors report 2 cases of rectal masses excised from dogs following a period of tenesmus and hematochezia. In both animals, the masses were composed of lymphoid tissue closely encompassing tubuloacinar structures. Immunohistochemistry and polymerase chain reaction antigen receptor rearrangement testing demonstrated that the lymphoid population was polyclonal, comprising T and B cells arranged in loosely follicular aggregates centered on the epithelial foci. In light of these findings, a diagnosis of lymphoglandular complex nodular hyperplasia was reported. To the authors' knowledge, this is the first report of this condition in dogs.
Placebo with carboplatin + paclitaxel OR nab-paclitaxel followed by placebo until progression. Participants assigned to placebo + chemotherapy will have the option of receiving open-label monotherapy INCMGA00012 in a crossover period after documentation of progressive disease.
Participants will receive nivolumab in combination with relatlimab by vein over about 30 minutes on Day 1 of each 28-day study cycle. You may receive up to 25 doses of the study drugs.
Patients receive cyclophosphamide IV continuously, carboplatin IV continuously, and thiotepa IV continuously over 24 hours on days -7 to -4. Patients undergo ASCT on day 0.
Diabetes is a disease of glucose metabolism which in the United States in 2007 was estimated to effect at least 17.5 million people with type 2 diabetes mellitus accounting for approximately 90% to 95%. Poorly-controlled or treated type 2 diabetes is associated with a variety of health risks, including heart disease, stroke, renal failure, amputations,and blindness and is the seventh leading cause of death in the United States (NDIC, National Diabetes Statistics, 2011). A large number of medical treatments are available yet approximately 67% of patients in the United States with type 2 diabetes are unable to reach levels of hemoglobin A1C less than 6.5%, which is the target level set by the American Association of Clinical Endocrinologists (AACE, State of Diabetes in America, 2011). In patients with type 2 diabetes mellitus who are also morbidly obese, certain bariatric surgical procedures have shown improvement in the control of type 2 diabetes in addition to the expected weight loss effects. However, clinical investigations have pointed to a mechanism other than just weight loss in the improvement of type 2 diabetes in these patients and raised the possibility of utilizing the same mechanism in non-morbidly obese patients. Subsequent basic science research in 2004 involving a surgical bypass procedure of the proximal intestine in non-obese mice with type 2 diabetes mellitus showed remission of diabetes in the majority of mice and marked improvement over medical treatment in the remaining mice (13). Human clinical trials have been conducted in various locations worldwide and have produced similar results to the animal study; a call has been made for studies of new surgical procedures for the treatment of type 2 diabetes in IRB-approved clinical trials (39). In several studies, the duodenal exclusion, which is a procedure which bypasses the duodenum and proximal jejunum and leaves the stomach intact, has been shown to cause remission or marked improvement in type 2 diabetes mellitus without significant weight loss in non-morbidly obese patients. However, no study within the United States has compared the effect of this surgical procedure upon type 2 diabetes with the effect of conventional medical treatment of type 2 diabetes in a controlled clinical trial. In this clinical study, the investigators propose to directly compare the treatment of type 2 diabetes mellitus in non-morbidly obese humans by a surgical bypass of the duodenum and proximal jejunum to the treatment of a similar group of humans treated with conventional medical therapy. Our hypothesis is that a non-bariatric surgical procedure, the laparoscopic duodenal exclusion, will provide improved treatment of type 2 diabetes mellitus in non-morbidly obese patients when compared to conventional medical treatment. The measures of the treatment of type 2 diabetes mellitus in which a difference is expected to be observed are glycosylated hemoglobin A1C (HbA1C), fasting glucose, and insulin resistance. The investigators propose a prospective, controlled, non-randomized clinical trial to test this hypothesis.
The invention relates to lutein ester or lutein emulsion and a preparation method of the lutein ester or lutein emulsion, and aims at solving the problems that the stability and the water solubility of the lutein ester or lutein are poor, and the bioavailability is low. The emulsion is composed of the lutein ester or lutein, a solvent, an emulsifying agent, an auxiliary emulsifying agent, water and the like. The transparent or semi-transparent O/W type lutein ester emulsion is prepared by adopting a micro-emulsifying technology. The method is easy to operate and low in energy consumption, and is suitable for industrial production. The prepared lutein ester emulsion is uniform and has the strong stability, and can be diluted by adding the water at any ratio; and meanwhile, the system compatibility is good, and a plurality of beneficial components including amino acids, minerals, probiotics and the like can be compounded. The lutein ester or lutein emulsion can be widely applied to industries including health products, functional beverages, cosmetics, medicines and the like.
OBJECTIVE: To determine the associations between neighborhood characteristics and chronic pain during childhood and adolescence in the United States, 2020-2021.
METHODS: Cross-sectional analysis of the 2020 and 2021 National Survey of Children's Health. National Survey of Children's Health grouped parents' responses to questions about neighborhood characteristics into 5 categories: neighborhood support, neighborhood safety, school support, neighborhood amenities, and the presence of detracting neighborhood elements. Chronic pain was defined as parents reporting their children had "frequent or chronic difficulty with repeated or chronic physical pain, including headache or other back or body pain during the past 12 months." Multivariable Poisson regression analyses estimated associations between neighborhood characteristics and chronic pain, adjusted for sociodemographic characteristics.
RESULTS: The sample contained 55,387 children (6 to 17 years), weighted to represent 44 million nationally. Children had significantly increased rates of chronic pain if they lived in neighborhoods that were unsupportive, unsafe, had unsafe schools, fewer amenities, and greater numbers of detracting elements ( P <0.0001). After adjusting for covariates, children had significantly increased chronic pain if they lived in neighborhoods that were not supportive (adjusted prevalence rate ratio=1.7 (95% CI: 1.5-1.9, P <0.0001), with similar patterns observed for living in neighborhoods characterized as not safe, that did not have safe schools, with fewer amenities, and/or more detracting elements.
DISCUSSION: Disadvantageous neighborhood characteristics are associated with pediatric chronic pain prevalence. Future research should investigate the underlying mechanisms of this association and guide neighborhood interventions aimed at preventing and decreasing childhood chronic pain and its associated burdens.
Participants allocated to this condition will receive 6-weeks of home-delivered pre-prepared ketogenic diet (KD) meals (3 meals/day, snacks) from a vetted ketogenic diet food supplier. The 6-week intervention includes a weekly 30-minute dietary counselling call with a registered dietitian to support following a ketogenic diet. Participants receive educational materials with information about foods that are compatible with the diet, common symptoms and how to manage them, and strategies to help maintain the diet during and after the 6-week intervention period.
N-Acetylcysteine effervescent tablets. 1 900mg tablet once a day for 1 week, then 1 900mg tablet twice a day for 1 week and then 1 900mg tablet three times a day for the remaining 10 weeks of the trial.
Nitric oxide (NO) interacts with hemoglobin (Hb) at its metal centers, whereas S-nitrosothiols (RSNOs) can donate the NO group to β93 cysteine residues, thereby shielding the NO functionality from heme inactivation. S-nitrosylation of Hb is under the allosteric control of oxygen and the oxidation state of heme. NO group release from S-nitrosohemoglobin (SNO-Hb) is further facilitated by intracellular low molecular weight thiols, forming RSNOs which can be exported from the erythrocyte to regulate blood pressure. Hence, a dynamic cycle is established in which S-nitrosylation of Hb is initiated in the lung following oxygenation of red blood cells and is completed by SNO-Hb metabolism during arterial-venous transit. SNO-Hb can be formed by reaction of Hb with S-nitrosothiol. This procedure avoids oxidation of the heme. SNO-Hb in its various forms and combinations thereof (oxy, deoxy, met; S-nitrosylated to various extents) can be administered to a mammal in a method of therapy where it is desired to oxygenate, to scavenge free radicals, or to release NO groups to tissues. Thiols can also be administered to enhance the transfer of NO groups. Examples of conditions to be treated by SNO-Hb therapy include ischaemic injury, hypertension, angina, reperfusion injury and inflammations.
Flucytosine Capsules, USP are indicated only in the treatment of serious infections caused by susceptible strains of Candida and/or  Cryptococcus. 

Candida: Septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. Limited trials in pulmonary infections justify the use of flucytosine. 

Cryptococcus: Meningitis and pulmonary infections have been treated effectively. Studies in septicemias and urinary tract infections are limited, but good responses have been reported. 

Flucytosine Capsules, USP should be used in combination with amphotericin B for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to Flucytosine Capsules, USP (see MICROBIOLOGY).
The recommended dose of paliperidone for the treatment of schizophrenia is 6 mg once daily, administered in the morning. Initial dose titration is not required. Some patients may benefit from lower or higher doses within the recommended range of 3 mg to 12 mg once daily. Dosage adjustment, if indicated, should occur only after clinical reassessment. When dose increases are indicated, increments of 3 mg/day are recommended and generally should occur at intervals of more than 5 days.
PURPOSE: Medicinal herb cream using ginkgo leaves as a main ingredient is provided. It further contains extracts of clove, Arisaema amurense for. serratum (Nakai) Kitagawa., Phytolacca esculenta and cinnamon. It reinforces the activity of a capillary. CONSTITUTION: Medicinal herb cream is manufactured by the steps of: washing ginkgo leaves and boiling them in water to obtain vapor; liquifying the vapor and mixing with the extract of clove, Arisaema amurense for. serratum (Nakai) Kitagawa., Phytolacca esculenta, cinnamon, Angelica uchiyamana and Coriolus versicolor; and adding 5-10% of chitosan to the mixture. The extract is obtained by boiling clove, Arisaema amurense for. serratum (Nakai) Kitagawa., Phytolacca esculenta, Angelica uchiyamana, Coriolus versicolor and cinnamon in a mixing ratio of 2:2:2:1:1:1 in water.
This is a prospective non-randomized clinical trial that aims to determine the efficacy and toxicity of targeted anticancer drugs or combinations that are approved or under review by EMA, FDA or PMDA and are used for treatment of patients with advanced cancer with a potentially actionable variant as revealed by a genomic, RNA-molecular or protein expression test. The study also aims to facilitate patient access to approved targeted therapies that are contributed to the program by collaborating pharmaceutical companies and to perform next generation sequencing and further deeper analysis on tumor biopsies and/or liquid biopsies for biomarker analyses and resistance mechanisms. Eligible patients have an advanced cancer for which standard treatment options no longer exist and acceptable performance status and organ function. A tumour DNA, RNA or protein expression analysis is required and the results must identify at least one potentially actionable molecular variant as defined in the protocol. Molecular profiling will be utilized to determine an appropriate drug(s) from among those available in the protocol. Drug selection will be guided by a list of potential profiles, the molecular tumor board and databases of identified targets for review and approval of the recommended treatment. The protocol-specified treatment will be administered to the patient once any drug- and disease specific eligibility criteria and overall study criteria are met. Data for standard efficacy outcomes including tumor response, progression-free and overall survival as well as duration of treatment will be collected for all patients receiving treatment within the trial. In addition, treatment related toxicity will be collected according to CTCAE 5.0.
The invention discloses a pharmaceutical composition comprising phenylephrine ora pharmaceutically acceptable salt thereof and an erodible layer which is fororal administration wherein the composition delivers phenylephrine or a pharmaceuticallyacceptable salt thereof via absorption in the colon. The pharmaceutical compositioncomprises a core comprising phenylephrine or a pharmaceutically acceptablesalt thereof and an erodible layer which is in a time-dependent, pH-dependent,or colon-specific enzyme-dependent erodible layer that degrades to exposethe core to release phenylephrine in the colon. In one preferred embodiment,the erodible layer encases the core. The composition optionally further comprisesphenylephrine in the erodible layer or other additional layer(s). The pharmaceuticalcomposition can further comprise one or more additional therapeutically activeagents selected from one or more of the group consisting of antihistamines, analgesics,anti-pyretics, and non-steroidal anti-in flammatory agents. The inventionalso discloses methods of administering phenylephrine via the colon, therebyincreasing the bioavailable amount of therapeutically active unconjugatedphenylephrine relative to the total phenylephrine in the plasma.
Sex and gender are distinct terms that must be used correctly. Data regarding sex and gender may be collected using a 2-step method that separates biological sex and self-reported gender identity. The PhenX Toolkit, funded by the National Institutes of Health (NIH), is one tool that provides investigators with recommended standard data-collection protocols. Another tool is the Diversity Minimal Item Set questionnaire. Importantly, sex and gender interact: for example, pain has both biological aspects (sex differences in electrical, ischemic, thermal, pressure, and muscle pain sensitivity) and cultural aspects (gender factors in how people report pain and how physicians understand and treat pain in patients). Gender norms, identity, and relations all impact patient care. Gender norms, for instance, may influence how a person experiences pain, gender identity may influence a person's willingness to report pain, and gender relations may influence a physician's gendered expectations in relation to a patient's gendered behaviors. Clinicians may perceive women's pain to be psychological; as a result, women may receive more nonspecific diagnoses, wait longer for treatment, and receive more antidepressants and fewer analgesics than men. Research on gender-diverse people and pain is just now emerging. Resources for methods of reporting include The Lancet, Nature, and the Sex and Gender Equity in Research (SAGER) Guidelines. We must consider all relevant factors intersecting with sex and gender, including age, disabilities, educational background, ethnicity, family configuration, geographic location, race, sexuality, social and economic status, sustainability, and more.
Patients receive an imaging agent via injection and undergo planar imaging and SPECT/CT over 1-2 hours. Patients then undergo SLN biopsy.